Article
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Journal of gastroenterology and hepatology - 1 Mar 2018
Liu Chen-Hua, Liu Chun-Jen, Su Tung-Hung, Yang Hung-Chih, Hong Chun-Ming, Tseng Tai-Chung, Chen Pei-Jer, Chen Ding-Shinn, Kao Jia-Horng
Abstract excerpt
BACKGROUND AND AIM: The real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) remain limited for East Asian hepatitis C virus genotype 1b (HCV-1b) patients. The study aimed to evaluate the antiviral responses of PrOD-based regimens for HCV-1b patients in Taiwan. METHODS: The study performed a retrospective analysis of 103 HCV-1b patients receiving PrOD with or without...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.